Bloodstream infection (BSI) is one of the major infectious complications in immunocompromised patients, leading to high morbidity and mortality. Gram-negative bacilli, especially those multi-resistant strains are the most common pathogens seen in this cohort of patients. Due to the insufficient inflammatory response, there is a lack of specific clinical manifestations of BSI in immunocompromised patients and therefore identification of biomarkers is required to help clinical diagnosis. A prolonged duration of antibiotic therapy should be considered in immunocompromised patients with BSI.